Combination of estramustine, paclitaxel, and tegafur-uracil (ETU) in patients with metastatic hormone-refractory prostate cancer (mHRPC): Efficacy and safety results of a multicenter phase II study

被引：0
|
作者：
Fitoussi, O.
Guichard, F.
Hirt, S.
Dohollou, N.
Bureau, C.
Auduhy, F.
Guichard, P.
机构：
[1] Polyclin Bordeaux N Aquitaine, Bordeaux, France
[2] Merck Lipha Sante, Lyon, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.16027
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
16027
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Retrospective Analysis of an Oral Combination of Dexamethasone, Uracil plus Tegafur and Cyclophosphamide for Hormone-refractory Prostate Cancer
    Hatano, Koji
    Nonomura, Norio
    Nishimura, Kazuo
    Kawashima, Atsunari
    Mukai, Masatoshi
    Nagahara, Akira
    Nakai, Yasutomo
    Nakayama, Masashi
    Takayama, Hitoshi
    Tsujimura, Akira
    Okuyama, Akihiko
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2011, 41 (02) : 253 - 259
  • [32] A phase II trial of deferoxamine in patients with hormone-refractory metastatic prostate cancer
    Dreicer, R
    Kemp, JD
    Stegink, LD
    Cardillo, T
    Davis, CS
    Forest, PK
    See, WA
    CANCER INVESTIGATION, 1997, 15 (04) : 311 - 317
  • [33] Phase I trial of weekly paclitaxel plus oral estramustine phosphate in patients with hormone-refractory prostate cancer
    Haas, N
    Roth, B
    Garay, C
    Yeslow, G
    Entmacher, M
    Weinstein, A
    Rogatko, A
    Babb, J
    Minnitti, C
    Flinker, D
    Gillon, T
    Hudes, G
    UROLOGY, 2001, 58 (01) : 59 - 64
  • [34] A phase II study of estramustine, docetaxel, and Exisulind in patients with hormone-refractory prostate cancer: Results of cancer and Leukemia Group B trial 90004
    Dawson, Nancy A.
    Halabi, Susan
    Ou, San-San
    Biggs, David D.
    Kessinger, Anne
    Vogelzang, Nicholas
    Clamon, Gerald H.
    Nanus, David M.
    Kelly, W. Kevin
    Small, Eric J.
    CLINICAL GENITOURINARY CANCER, 2008, 6 (02) : 110 - 116
  • [35] Weekly administration of docetaxel in combination with estramustine and celecoxib in patients with advanced hormone-refractory prostate cancer:: final results from a phase II study Clinical Studies
    Carles, J.
    Font, A.
    Mellado, B.
    Domenech, M.
    Gallardo, E.
    Gonzalez-Larriba, J. L.
    Catalan, G.
    Alfaro, J.
    del Alba, A. Gonzalez
    Nogue, M.
    Lianes, P.
    Tello, J. M.
    BRITISH JOURNAL OF CANCER, 2007, 97 (09) : 1206 - 1210
  • [36] An open-label, noncomparative phase II trial to evaluate the efficacy and safety of docetaxel in combination with gefitinib in patients with hormone-refractory metastatic prostate cancer
    Salzberg, Marc
    Rochlitz, Christoph
    Morant, Rudolf
    Thalmann, George
    Pedrazzini, Augusto
    Roggero, Enrico
    Schoeneberger, Astrid
    Knuth, Alexander
    Borner, Markus
    ONKOLOGIE, 2007, 30 (07): : 355 - 360
  • [37] Vinorelbine and prednisone in older cancer patients with hormone-refractory metastatic prostate cancer - A phase II study
    Tralongo, P
    Bollina, R
    Aiello, R
    Di Mari, A
    Moruzzi, G
    Beretta, G
    Mauceri, G
    Conti, G
    TUMORI JOURNAL, 2003, 89 (01): : 26 - 30
  • [38] Sequential mitoxantrone/prednisone followed by docetaxel/estramustine in patients with hormone refractory metastatic prostate cancer: results of a phase II study
    Font, A
    Murias, A
    Arroyo, FRG
    Martin, C
    Areal, J
    Sanchez, JJ
    Santiago, JA
    Constenla, M
    Saladie, JM
    Rosell, R
    ANNALS OF ONCOLOGY, 2005, 16 (03) : 419 - 424
  • [39] The combination of estramustine and mitoxantrone in hormone-refractory prostate cancer: A phase II feasibility study conducted by the hellenic cooperative oncology group
    Samelis, GF
    Skarlos, D
    Bafaloukos, D
    Kosmidis, P
    Anagnostopoulos, A
    Aravantinos, G
    Dimopoulos, MA
    UROLOGY, 2003, 61 (06) : 1211 - 1215
  • [40] A phase II Hoosier Oncology Group study of vinorelbine and estramustine phosphate in hormone-refractory prostate cancer
    Sweeney, CJ
    Monaco, FJ
    Jung, SH
    Wasielewski, MJ
    Picus, J
    Ansari, RH
    Dugan, WM
    Einhorn, LH
    ANNALS OF ONCOLOGY, 2002, 13 (03) : 435 - 440
12345